Connecting oncology professionals with relevant clinical trials

Selected clinical trial

METIMMOX-3: Biomarker-Selected Short-Course Oxaliplatin-Based Chemotherapy and Bevacizumab Alternating With Tislelizumab in Metastatic MSS/pMMR Colorectal Cancer

Sponsor: Akershus University Hospital

Phase: 2

Disease: Metastatic colorectal cancer, Microsatellite-stable colorectal cancer, Mismatch-repair-proficient colorectal cancer

EU trial number: 2026-526317-29-00

Population: Patients with previously untreated unresectable abdominal metastases from microsatellite-stable, mismatch-repair-proficient colorectal carcinoma, initially receiving oxaliplatin-based chemotherapy and bevacizumab; only those with intermediate tumor mutational burden (≥9 mutations/Mb) or BRAF V600E mutation continue to alternating tislelizumab treatment.

Register Investigator Interest

Interested in offering this trial to suitable patients?